Glaukos' (GKOS) first-quarter 2024 results showcase growth in revenues while earnings miss the Zacks consensus Estimate. Loss at the operating level raises concern as well.
Glaukos (GKOS) delivered earnings and revenue surprises of -20.69% and 8.83%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Medical Device companies' quarterly results are likely to reflect strength in customer demand. Let's see how COR, GKOS, SRDX and ARAY are placed ahead of their earnings releases.